Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Entyvio Filed for Crohn’s Disease in Japan: Takeda
July 19, 2018
- Teva Takeda to Wind Up Sale of 48 Products towards Stable Supply
July 18, 2018
- Xofluza Hits Primary Endpoint in High Risk Flu Patients: Shionogi
July 18, 2018
- Chugai to Develop ROS1/TRK Inhibitor Entrectinib in Japan
July 18, 2018
- AZ Initiates PIII Study of Nexium for Pediatric Indications at Request of AMED, Pediatric Society
July 18, 2018
- FDA OKs Xtandi for Non-Metastatic Prostate Cancer
July 18, 2018
- Epadel to Enter Clinical Study in China: Mochida, Sumitomo Dainippon
July 18, 2018
- Lilly Japan Marks Opening of New Kobe Headquarters
July 17, 2018
- Taiho Exercises Option to Gain Asian Rights to Arcus’ I/O Candidate
July 17, 2018
- Takeda Jettisons Japan Rights to Obesity Drug OBLEAN after Long Listing Limbo
July 17, 2018
- Ninlaro Hits Primary Endpoint in Post-Transplant Multiple Myeloma: Takeda
July 13, 2018
- Otsuka Ventures into Antibody Space with Visterra Buyout
July 12, 2018
- Kyushu Univ. Spinoff, Nagoya Upstart Launch Joint Research for AMD Treatment
July 12, 2018
- 1st Patient Dosed in PIII Enfortumab Vedotin Study: Astellas/Seattle Genetics
July 11, 2018
- Repatha Label Updated in Japan to Add CV Risk Reduction Data
July 11, 2018
- Takeda Clinches Key US Clearance for Shire Takeover
July 10, 2018
- Nichi-Iko Ties Up with Sunward for Malaysia, Singapore Biz
July 10, 2018
- No Major Damage for Drug Makers, Wholesaler Logistics: West Japan Downpours
July 10, 2018
- Ethical Drug Sales Up 2.6% in May: Crecon
July 9, 2018
- Eisai/Biogen Say Alzheimer’s Candidate BAN2401 Delivered Positive Data at 18 Month Analysis
July 9, 2018
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…